Results 81 to 90 of about 180,829 (383)

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]

, 2019
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis, Bittner, Aitomi, Denker, Sophy, Frick, Mareike, Hummel, Michael, Kase, Julia, Na, Il-Kang, Schmitt, Clemens A.   +7 more
core   +2 more sources

Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab

Science, 2020
Clustering for the kill Cluster of differentiation 20 (CD20) is a membrane protein that defines most B cell populations and is the target of therapeutic antibodies to treat malignancies and autoimmune disorders. Rougé et al. present the structure of CD20
L. Rougé, Nancy Chiang, M. Steffek, Christine Kugel, T. Croll, C. Tam, A. Estevez, C. Arthur, C. Koth, C. Ciferri, E. Kraft, J. Payandeh, G. Nakamura, J. T. Koerber, A. Rohou   +14 more
semanticscholar   +1 more source

Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Updated Review of Clinical Outcomes and the Molecular Pathogenesis

Gut and Liver, 2009
In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H.
doaj   +1 more source

Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells

Vaccines, 2022
B-cell lymphoma is a group of malignant proliferative diseases originating from lymphoid tissue with different clinical manifestations and biological characteristics.
Yanlong Liu, Kexin Ao, Fuxiang Bao, Yi Cheng, Yanxia Hao, Huimin Zhang, Shan Fu, Jiaqi Xu, Qiyao Wu   +8 more
doaj   +1 more source

Malignant lymphomas (ML) and HIV/AIDS Infection in Tanzania. [PDF]

, 2008
\ud HIV infection is reported to be associated with some malignant lymphomas (ML) so called AIDS-related lymphomas (ARL), with an aggressive behavior and poor prognosis.
Amos R Mwakigonja, Ephata E Kaaya, Edward M Mgaya, C Chassagne-Clement, AM Levine, DM Parkin, DM Parkin, A Carbone, VL Ng, E Castanos-Velez, P Biberfeld, JW Said, ST Lim, J Tomas Navarro, E Kaaya, RJ Pelstring, I Joab, OW Mwanda, C Bellan, JN Kitinya, JL Eshleman, PJ Cook, S Lazzi, DM Parkin, AR Mwakigonja, S Franceschi, D Baris, V Beral, ST Lim, SG Fisher, S de Sanjose, EM Mgaya, SP Chai, RL Mbise, Z Aziz, OW Mwanda, LK Tumwine, KC Chang, J Andersson, V Dinand, C Cohen, ST Lim, J Orem, TR Cote, M Llanos, E Castanos-Velez   +45 more
core   +2 more sources

Frailty Exacerbates Disability in Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks, Anna Wolska, Diala Ghazal, Dejan Jakimovski, Bianca Weinstock‐Guttman, Alexander Burnham, Niels Bergsland, Michael G. Dwyer, Alan T. Remaley, Robert Zivadinov, Murali Ramanathan   +10 more
wiley   +1 more source

ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES

Медицинская иммунология, 2014
. Our understanding of the multiple physiological and pathological functions of B-cells continues to expand at a fascinating rate. As pathogenic elements in the development of autoimmune diseases, B-cells have become the focus of new therapeutics.
A. L. Masliansky, V. I. Mazurov, E. G. Zotkin, E. P. Ilivanova, Areg A. Totolian   +4 more
doaj   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages [PDF]

, 2015
We have read with great interest the recent article of Kohrt, H.E. et al1 showing that Ibrutinib prevented NK cell mediated cytotoxicity of antibody-coated CLL cells in vitro.
Almejún, María Belén, Bezares, Raimundo F., Borge, Mercedes, Cabrejo, María, Colado, Ana, Fernández Grecco, Horacio, Gamberale, Romina, Giordano, Mirta Nilda, Podaza, Enrique Arturo   +8 more
core   +2 more sources

Anti-CD20 monoclonal antibodies: reviewing a revolution

Human Vaccines & Immunotherapeutics, 2018
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice.
J. M. L. Casan, J. Wong, M. J. Northcott, S. Opat   +3 more
doaj   +1 more source